Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of pCAR-19B in Relapsed/Refractory CD19+ Non-Hodgkin Lymphoma
NCT05420493Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of priscabtagene autoleucel in non-Hodgkin lymphoma (NHL), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after CAR-T cells infusion at 28 days and Objective response rate after CAR-T cells infusion at 3 months. Started Sep 2021; status: recruiting.
02
Drugs
priscabtagene autoleucel
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05420493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420493.